Hepion Pharmaceuticals, Inc. (HEPA)
OTCMKTS · Delayed Price · Currency is USD
0.0652
+0.0117 (21.87%)
At close: Jul 27, 2026
Hepion Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.6 | 1.83 | 0.41 | 14.79 | 51.19 | 91.35 |
Cash & Short-Term Investments | 2.6 | 1.83 | 0.41 | 14.79 | 51.19 | 91.35 |
Cash Growth | -43.25% | 349.81% | -97.25% | -71.11% | -43.96% | 124.30% |
Prepaid Expenses | 0.1 | 1.24 | 1.21 | 2.7 | 5.31 | 6.1 |
Total Current Assets | 2.71 | 3.07 | 1.61 | 17.49 | 56.5 | 97.45 |
Property, Plant & Equipment | - | - | - | 0.24 | 0.13 | 0.46 |
Goodwill | - | - | - | - | - | 1.87 |
Other Intangible Assets | - | - | - | - | 3.19 | 3.19 |
Other Long-Term Assets | - | - | - | 0.36 | 0.43 | 0.58 |
Total Assets | 2.71 | 3.07 | 1.61 | 18.09 | 60.24 | 103.55 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.14 | 0.17 | 0.22 | 2.35 | 2.67 | 2.45 |
Accrued Expenses | 0.35 | 0.08 | 0.02 | 1.74 | 4.8 | 2.51 |
Short-Term Debt | - | 0.05 | 2.9 | - | - | - |
Current Portion of Leases | - | - | - | 0.12 | 0.05 | 0.27 |
Other Current Liabilities | 0.25 | - | - | 1.09 | 0.37 | 2.99 |
Total Current Liabilities | 0.74 | 0.3 | 3.14 | 5.29 | 7.89 | 8.21 |
Long-Term Leases | - | - | - | 0.09 | - | 0.05 |
Long-Term Deferred Tax Liabilities | - | - | - | - | 0.41 | 0.41 |
Other Long-Term Liabilities | 0.11 | 0.1 | 0.33 | 5.43 | 2.09 | 1.89 |
Total Liabilities | 0.85 | 0.4 | 3.48 | 10.81 | 10.39 | 10.56 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0.01 |
Additional Paid-In Capital | 247.06 | 247.06 | 234.25 | 230.29 | 223.95 | 224.79 |
Retained Earnings | -246.91 | -246.1 | -237.82 | -224.63 | -175.7 | -133.5 |
Comprehensive Income & Other | 0.01 | 0.01 | 0.01 | -0.08 | -0.09 | - |
Total Common Equity | 0.16 | 0.97 | -3.56 | 5.59 | 48.16 | 91.29 |
Shareholders' Equity | 1.86 | 2.67 | -1.86 | 7.28 | 49.86 | 93 |
Total Liabilities & Equity | 2.71 | 3.07 | 1.61 | 18.09 | 60.24 | 103.55 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 0.05 | 2.9 | 0.21 | 0.05 | 0.32 |
Net Cash (Debt) | 2.6 | 1.77 | -2.49 | 14.58 | 51.14 | 91.03 |
Net Cash Growth | -35.90% | - | - | -71.49% | -43.83% | 127.72% |
Net Cash Per Share | 0.22 | 0.19 | -20.29 | 183.55 | 670.81 | 1295.05 |
Filing Date Shares Outstanding | 29.12 | 11.62 | 10.98 | 0.11 | 0.08 | 0.08 |
Total Common Shares Outstanding | 11.62 | 11.62 | 0.14 | 0.1 | 0.08 | 0.08 |
Working Capital | 1.97 | 2.77 | -1.53 | 12.2 | 48.61 | 89.25 |
Book Value Per Share | 0.01 | 0.08 | -25.57 | 57.96 | 631.77 | 1197.69 |
Tangible Book Value | 0.16 | 0.97 | -3.56 | 5.59 | 44.97 | 86.23 |
Tangible Book Value Per Share | 0.01 | 0.08 | -25.57 | 57.96 | 589.92 | 1131.29 |
Machinery | - | - | - | 0.41 | 0.39 | 0.39 |